
GEP testing to identify patients likely to benefit from ART therapy
DecisionDx-SCC provides an independent risk of metastasis score as well as identifies patients likely to benefit from adjuvant radiation therapy (ART).
Independently validated to predict ART treatment benefit
DecisionDx-SCC has now been independently validated to predict ART treatment benefit in two studies comprising over 1,300 patients. Together, these two studies by Ruiz et al. in Future Oncology (2024) and Arron et al. in the Red Journal (2024) represent the largest published population of ART-treated high-risk SCC patients. Results from this study provide a validation of the performance of the previously reported (Arron et al. Red Journal 2024) benefit of ART for Class 2B tumors and a lack of benefit for Class 1 tumors and was conducted using 423 tumors from 399 patients from Brigham Women’s Health (BWH) and Cleveland Clinic. Given the consistency of the results from two independent cohorts, DecisionDx-SCC can aid in ART decision-making for patients with high-risk SCC tumors.
Future Oncology
Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile
International Journal of Radiation Oncology, Biology, and Physics
Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma and Specification of Benefit of Adjuvant Radiation Therapy
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART.
Patients with Class 1 test results, predicted to have a lower risk of metastasis, did not see an improvement in survival after receiving ART, which together indicates these patients may be able to avoid the treatment.to non-ART treated patients. In addition, in patients with a Class 1 (lower risk) test result there was a non-significant benefit from ART treatment.
Journal of Clinical and Aesthetic Dermatology
Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines
Integrating DecisionDx-SCC 40-GEP testing improves precision in multidisciplinary treatment recommendations for ART, imaging, and the risk/benefit analysis for these interventions when applying the Class results of the test.
A new consensus guideline publication in The Journal of Clinical and Aesthetic Dermatology (JCAD) highlights multidisciplinary (two radiation oncologists and three Mohs surgeons) consensus guidelines that recommend combining traditional staging with the 40-GEP test to allow for more accurate prognostic staging of SCC tumors, and to improve precision in multidisciplinary treatment recommendations, including the use of ART.
Hear from an expert
Discover how Radiation Oncologist, Ramesh Gopal, MD, PhD, integrates the DecisionDx-SCC test into his practice
